Mar 26, 2012Boston Scientific Supports New Clinical Trial to Evaluate Platinum Chromium Coronary Stents in Treating Heart Attack PatientsHORIZONS II AMI trial to enroll up to 10,000 patients worldwide, making it the largest randomized trial to study coronary stents in heart attack patients
Boston Scientific Corporation (NYSE: BSX) announces its support of the HORIZONS II AMI clinical trial, which is designed to evaluate the safety and efficacy of the PROMUS Element™ Plus...
Mar 25, 2012Landmark Analysis of Year Two Data From PLATINUM Workhorse Trial Demonstrates Superior Efficacy of PROMUS Element™ Platinum Chromium Stent Compared to PROMUS® (Xience V®) Stent
Boston Scientific Corporation (NYSE: BSX) announces two-year follow-up data from the pivotal PLATINUM Workhorse trial comparing the safety and effectiveness of the PROMUS Element™...
Mar 8, 2012Company gains first and only commercially available subcutaneous ICD technology to offer lifesaving therapy to patients at risk of sudden cardiac arrest
Boston Scientific Corporation (NYSE: BSX) announces the exercise of its option to acquire Cameron Health, Inc., a privately held company based in San Clemente, California. Cameron Health has...
Feb 25, 2012Analysis of Two Randomized Clinical Trials Identify No Cases of Longitudinal Stent Deformation With Boston Scientific Platinum Chromium StentsQuantitative Coronary Angiographic outcomes from PERSEUS and PLATINUM clinical trials presented at ACC 2012
Boston Scientific Corporation (NYSE: BSX) announces results from a quantitative coronary angiographic (QCA) analysis of the incidence of longitudinal stent deformation in the PERSEUS and PLATINUM...
Feb 2, 2012Boston Scientific annuncia il primo impianto e la commercializzazione in Europa dello Stent Promus Element™ PlusLo stent coronarico in platino e cromo con un sistema avanzato di delivery è adesso disponibile in Europa e in altri Paesi
Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi il primo impianto supaziente e la commercializzazione in Europa dello stent coronarico in platino e cromo a rilascio di Everolimus,...
Feb 1, 2012Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in EuropePlatinum chromium coronary stent with enhanced delivery system now available in Europe and other international countries
Boston Scientific Corporation (NYSE: BSX) announces first patient use and European market launch of the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System. The first...
Jan 26, 2012NICE Report Supports Safety and Effectiveness of Alair® System
Boston Scientific (UK) welcomes new guidance from the National Institute for Health and Clinical Excellence (NICE) on the use of Bronchial Thermoplasty (BT) to treat adult patients with severe...
May 9, 2004New data presented at WIP 2014 demonstrate sustained low back pain relief with the Boston Scientific Precision Spectra™ Spinal Cord Stimulator System [EN]Advanced Illumina™ 3D Programming Software Provides Highly Significant Pain Relief in Study Patients
New retrospective data highlighting the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate the device provided sustained and highly...